<SEC-DOCUMENT>0000914475-24-000229.txt : 20241220
<SEC-HEADER>0000914475-24-000229.hdr.sgml : 20241220
<ACCEPTANCE-DATETIME>20241220080642
ACCESSION NUMBER:		0000914475-24-000229
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241220
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20241220
DATE AS OF CHANGE:		20241220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		241565167

	BUSINESS ADDRESS:	
		STREET 1:		6027 EDGEWOOD BEND COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20241220.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:207c4596-2ed7-4252-8a4f-f0249e12e453,g:c1a2a4f9-1f35-4946-9411-2b13040566c3,d:b403bac6d4e9441eb69f316903bb861f-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20241220</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20241220.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-20</xbrli:startDate><xbrli:endDate>2024-12-20</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib403bac6d4e9441eb69f316903bb861f_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">December 20, 2024</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="nbix-20241220_g1.jpg" alt="nbix.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-22705</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0525145</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Commission</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">6027 Edgewood Bend Court</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92130</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">617-7600</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr style="height:0pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib403bac6d4e9441eb69f316903bb861f_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01.&#160;&#160;&#160;&#160;Other Events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2024, Neurocrine Biosciences, Inc. (&#8220;Neurocrine Biosciences&#8221; or the &#8220;Company&#8221;) issued a press release announcing that CRENESSITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (crinecerfont) capsules and oral solution are now available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a wholesale acquisition cost for CRENESSITY in the United States of approximately $38,333 for a 30-day supply.  For pediatric patients weighing less than 20 kilograms, the wholesale acquisition cost for a 30-day supply will be approximately $19,167. The Company expects 90% of patients will have a monthly copay of $12 or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical facts, this Current Report on Form 8-K contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency; the ability of the Company to ensure patients have access to CRENESSITY; and the Company&#8217;s expectations regarding coverage and reimbursement from third-party payors for CRENESSITY. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences&#8217; business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; and other risks described in the Company&#8217;s periodic reports filed with the Securities and Exchange Commission, including without limitation the Company&#8217;s quarterly report on Form 10-Q for the quarter ended September 30, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix20241220-exhibit991.htm">Press Release issued by Neurocrine Biosciences, Inc. on December 20, 2024</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib403bac6d4e9441eb69f316903bb861f_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: December 20, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix20241220-exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9e4977fbd33d4ba69dd135c68d1d1e18_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Neurocrine Biosciences Announces Commercial Availability of <br>CRENESSITY&#8482; (crinecerfont) for Children and Adults <br>With Classic Congenital Adrenal Hyperplasia </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;CAH-trained pharmacists are available 24&#47;7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacy</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;Neurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providers</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">SAN DIEGO, Dec. 20, 2024 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) today announced CRENESSITY&#8482; (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is a first-in-class therapy for classic CAH that directly reduces adrenocorticotropic hormone and downstream adrenal androgen production. It is the first and only classic CAH treatment that allows people to take lower doses of glucocorticoids while maintaining or improving their androgen levels.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;Individuals with CAH and their families have faced ongoing challenges with managing the condition with high-dose steroids alone for the past 70 years,&#8221; said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. &#8220;We&#8217;re proud to now provide CRENESSITY to the community, and we are committed to supporting patients in obtaining treatment with CRENESSITY through our comprehensive assistance program.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CRENESSITY is exclusively available through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescriptions. PANTHERx Rare has CAH-trained pharmacists available 24&#47;7 to patients, caregivers and healthcare providers to answer questions and address concerns.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options specifically designed to ensure patients with CAH have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. The company expects 90% of patients will have a monthly copay of $12 or less. For more information, visit www.nbiaccess.com&#47;crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The U.S. Food and Drug Administration approval of CRENESSITY was supported by the largest-ever clinical trial program of classic CAH, the CAHtalystTM Pediatric study, conducted in ages four to 17, and the CAHtalyst Adult study. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">View the press release announcing the initial FDA approval of CRENESSITY here.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For more information about CRENESSITY, visit Crenessity.com.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About Congenital Adrenal Hyperplasia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About The CAHtalyst</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"> Studies </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Phase 3 CAHtalyst</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About CRENESSITY&#8482; (crinecerfont) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CRENESSITY&#8482; is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg&#47;mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Important Information</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Approved Uses</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">IMPORTANT SAFETY INFORMATION</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Do not take CRENESSITY if you&#58; </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CRENESSITY may cause serious side effects, including&#58; </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Allergic Reactions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Tell your healthcare provider about all the medicines you take</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">, including prescription and over-the counter medicines, vitamins, and herbal supplements.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">The most common side effects of CRENESSITY in adults include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">The most common side effects of CRENESSITY in children include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">headache, stomach pain, tiredness, nasal congestion, and nose bleeds. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov&#47;medwatch or call 1-800-FDA-1088.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Dosage Forms and Strengths&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg&#47;mL.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Please see full Prescribing Information.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About Neurocrine Biosciences, Inc. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose&#58; to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter) and Facebook. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">*in collaboration with AbbVie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency&#59; the value and benefits CRENESSITY brings to patients with CAH&#59; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY&#59; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following&#58; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY&#59; whether CRENESSITY receives adequate reimbursement from third-party payors&#59; the degree and pace of market uptake of CRENESSITY&#59; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY&#59; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties&#59; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY&#59; risks that post-approval CRENESSITY commitments or requirements may be delayed&#59; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY&#59; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company&#8217;s quarterly report on Form 10-Q for the quarter ended September 30, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Neurocrine Biosciences, Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Media&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Aimee White </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1-858-354-7865 </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">media&#64;neurocrine.com </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investors&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Todd Tushla </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1-858-617-7143 </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ir&#64;neurocrine.com </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#169; 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0294  12&#47;2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20241220.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:207c4596-2ed7-4252-8a4f-f0249e12e453,g:c1a2a4f9-1f35-4946-9411-2b13040566c3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20241220" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20241220">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20241220_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20241220_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20241220_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:207c4596-2ed7-4252-8a4f-f0249e12e453,g:c1a2a4f9-1f35-4946-9411-2b13040566c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b6ebadd1-7d77-47c0-8045-893dd61665fa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a7a7dab5-91dd-46c4-8f07-090e7da280c5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_92ceca4f-30a2-4266-99b9-736d1b010200_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fcefe330-5763-4ed9-9e6f-99ecb8a731ec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cf7b9e21-d69a-4886-9ce1-5425de39ddc2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_593b95fb-a97c-4c0e-8baf-139ea9b83e81_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_035a84e3-bcc4-46cc-9736-275b4f448b2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a6bc6101-96bf-4b35-8c10-87491b6e8d5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_baeb4d5e-1161-4912-a7ce-4cfc5c1af7d5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_47864c93-b9d2-4b4e-8fe1-0b1d0847c80b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_82aa5a73-c2c2-4a67-8927-ea8c525ebf51_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_07afe6fa-f4b0-4630-9061-749519c3bf7a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_df01e830-e459-4fb6-b79c-dd0afc800747_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b0c63356-749a-4dba-8797-25112b90f816_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_31eecdc8-9427-4bff-8999-06ddd5245fdd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aaa07cbd-4ef1-4777-a6cf-cc20808a9cb3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e02c70aa-de60-4d3f-907a-553b7be0a77d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d9346a06-207a-4c5e-92a8-9d2c229a510e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_86f379c7-7fc5-47e3-a198-b795d85fd971_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d547c094-ab91-4ab2-a5b1-617adb337ed7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9324728c-475e-4426-9ecc-70c82d0c68a9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_96102601-e893-4551-8582-3660b88612a9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20241220_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:207c4596-2ed7-4252-8a4f-f0249e12e453,g:c1a2a4f9-1f35-4946-9411-2b13040566c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20241220.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6b1ab197-9ef5-42e6-b13b-8b1179a3aac6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_DocumentType_6b1ab197-9ef5-42e6-b13b-8b1179a3aac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4a66170f-2108-4032-934d-4d4c69ab2eec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_DocumentPeriodEndDate_4a66170f-2108-4032-934d-4d4c69ab2eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_81c7c460-7fa6-4232-b65f-8f7d107211b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityRegistrantName_81c7c460-7fa6-4232-b65f-8f7d107211b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b40168c7-1a1e-493b-9739-621cf587b8ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b40168c7-1a1e-493b-9739-621cf587b8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a8712f83-d837-4701-a21d-67935a9a5b69" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityFileNumber_a8712f83-d837-4701-a21d-67935a9a5b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7e9972e1-e087-4a7d-ace9-316aef5e4e53" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityTaxIdentificationNumber_7e9972e1-e087-4a7d-ace9-316aef5e4e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0ef9795f-884f-43e2-8a60-991e753d2eab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityAddressAddressLine1_0ef9795f-884f-43e2-8a60-991e753d2eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_91f6a2d3-4684-4e8c-805c-bbe06d332fa8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityAddressCityOrTown_91f6a2d3-4684-4e8c-805c-bbe06d332fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dbaab88c-6492-4ff8-b0b7-bb0595cf93a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityAddressStateOrProvince_dbaab88c-6492-4ff8-b0b7-bb0595cf93a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5c0554f4-9b2e-4193-a38c-99edfcd252d8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityAddressPostalZipCode_5c0554f4-9b2e-4193-a38c-99edfcd252d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_409a8ee1-6a81-4f73-91a5-2d2e6292c2d6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_CityAreaCode_409a8ee1-6a81-4f73-91a5-2d2e6292c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86a41b1d-aff7-4bea-8ba4-4d42b22f3ed9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_LocalPhoneNumber_86a41b1d-aff7-4bea-8ba4-4d42b22f3ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5721be46-1fc8-4718-a458-4379ef705309" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_Security12bTitle_5721be46-1fc8-4718-a458-4379ef705309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c8af931d-fc74-4430-812c-d673f49f7de0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_TradingSymbol_c8af931d-fc74-4430-812c-d673f49f7de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c61bac2d-10d2-498c-aaed-bd125ae5ccf3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_SecurityExchangeName_c61bac2d-10d2-498c-aaed-bd125ae5ccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4cadb2ca-71b5-4f3a-a2bb-0469c24c3fb3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_WrittenCommunications_4cadb2ca-71b5-4f3a-a2bb-0469c24c3fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b981a61d-f1e0-4996-977b-31d9d003176c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_SolicitingMaterial_b981a61d-f1e0-4996-977b-31d9d003176c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_78aa22f9-7d0f-4838-bd76-e80601731a82" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_PreCommencementTenderOffer_78aa22f9-7d0f-4838-bd76-e80601731a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_8352cc7e-fe41-49c6-90f3-9d452f5b70c3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_8352cc7e-fe41-49c6-90f3-9d452f5b70c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d51caf17-861f-403c-8074-053c059738f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityEmergingGrowthCompany_d51caf17-861f-403c-8074-053c059738f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4476c86d-f31e-4bf5-90c5-3fb337e1e34e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_AmendmentFlag_4476c86d-f31e-4bf5-90c5-3fb337e1e34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ffbb27f5-b49a-441e-8cfb-837b3ccd8b96" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2869fd8f-08f6-41a4-b5e1-1613b6c38e5c" xlink:to="loc_dei_EntityCentralIndexKey_ffbb27f5-b49a-441e-8cfb-837b3ccd8b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nbix-20241220_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20241220_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
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M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
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MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
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MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
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M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45328953346544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 20, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 20,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6027 Edgewood Bend Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF1O@^D9*?1Z836OY/X?Q?U!+ P04    " #40)19GZ ;\+$"  #B#   #0
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M?P%02P$"% ,4    " #40)19!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -1 E%FP ]6B[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( -1 E%F97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ U$"46?$9JP](!   ?Q   !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( -1 E%F?H!OPL0(  .(,   -              "  8L,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ U$"469>*NQS     $P(   L
M ( !9P\  %]R96QS+RYR96QS4$L! A0#%     @ U$"46:K$(A8S 0  (@(
M  \              ( !4!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M -1 E%DD'INBK0   /@!   :              "  ; 1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -1 E%EED'F2&0$  ,\#   3
M              "  942  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  -\3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20241220.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="nbix-20241220.htm">nbix-20241220.htm</File>
    <File>nbix-20241220.xsd</File>
    <File>nbix-20241220_lab.xml</File>
    <File>nbix-20241220_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20241220_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nbix-20241220.htm": {
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20241220",
   "dts": {
    "inline": {
     "local": [
      "nbix-20241220.htm"
     ]
    },
    "schema": {
     "local": [
      "nbix-20241220.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20241220_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20241220_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.neurocrine.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20241220.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20241220.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000914475-24-000229-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-24-000229-xbrl.zip
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MKR^RYRWY2O8T9WPF<>X^\6FLP)%C"!$ ;\ D:O.!EHY*!I9W0N@=Y:$N.D$
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MHV.@HZ5E8&)@8+Q*$5IZ9A:FJ\S_UO\^Y-_;_[V+<K]*1TMW]?^SD-L K'0
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MO9""*9KCN?\( Z>PXHH(YI]I_\.R_W>&A?__LNQ_,^Q_MVL6<)6:BA(\:E8
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M<\92BM#WH.4X$-UU)[QV+_<):2R>#$B8TL,'0%6K<93>1C.$48Z2OEW#."C
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MHUMW)E\<R%08$BH-^*[HFZ1.EUY2N1%.=ZL!B+NU2<A:XH1/MX).OJF>=_;
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M\E_G?_M\428$-<]I+YCLOX;/-CPG6YW/B^/<[ME^B4I:Z^"K!XL/?+CPNF#
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MQE5L/6Z&:;'(@_(\'&?KW#"Q_NQ=RWOHR$S) 3@<MY6]91. U^*5?O2#(G<
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M::R-(.6&%!VU$EC_G@J1:%Y0Y?W[2P@<MXM%C#[#6.W3KQYRRFQ\_XIBH87
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M&%4#H *Y#PI\ O"7@CXL>)/'&EZ2MKXH\71PQ:M>B>1C=K$H6,%&8HN  /E
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M0M !1110 4444 %%%% !1110 4444 %%%% !1110!__94$L#!!0    ( -1
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MBT1I*PIG7>&5W0$C_UH<!$0Q=2!>J. DHG_A;D\C:E6F\G[S\3 1#=9JCA(
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M2O7WN<Y'HWW)E;/OY)_ ^H[_Z:W_ U!+ 0(4 Q0    ( -1 E%DMX,+S3A$
M ,1C   1              "  0    !N8FEX+3(P,C0Q,C(P+FAT;5!+ 0(4
M Q0    ( -1 E%G+21%N7P(  /\&   1              "  7T1  !N8FEX
M+3(P,C0Q,C(P+GAS9%!+ 0(4 Q0    ( -1 E%E8;/FC/D8  -)'   4
M          "  0L4  !N8FEX+3(P,C0Q,C(P7V<Q+FIP9U!+ 0(4 Q0    (
M -1 E%DC*A,,#@H  'U4   5              "  7M:  !N8FEX+3(P,C0Q
M,C(P7VQA8BYX;6Q02P$"% ,4    " #40)19<.<2)ZH&  #B,   %0
M        @ &\9   ;F)I>"TR,#(T,3(R,%]P<F4N>&UL4$L! A0#%     @
MU$"46:H;86UT&   @6L  !L              ( !F6L  &YB:7@R,#(T,3(R
F,"UE>&AI8FET.3DQ+FAT;5!+!08     !@ & (\!  !&A      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>nbix-20241220_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20241220.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-12-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">6027 Edgewood Bend Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">617-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
